392 related articles for article (PubMed ID: 25786656)
1. Paradoxical and contradictory effects of imatinib in two cell line models of hormone-refractory prostate cancer.
Cardoso HJ; Vaz CV; Correia S; Figueira MI; Marques R; Maia CJ; Socorro S
Prostate; 2015 Jun; 75(9):923-35. PubMed ID: 25786656
[TBL] [Abstract][Full Text] [Related]
2. The G-quadruplex ligand, SYUIQ-FM05, targets proto-oncogene c-kit transcription and induces apoptosis in K562 cells.
Shen FH; Jin J; Li J; Wang Y; Zhu SH; Lu YJ; Ou TM; Huang ZS; Huang M; Huang ZY
Pharm Biol; 2013 Apr; 51(4):447-54. PubMed ID: 23363047
[TBL] [Abstract][Full Text] [Related]
3. Imatinib enhances human melanoma cell susceptibility to TRAIL-induced cell death: Relationship to Bcl-2 family and caspase activation.
Hamaï A; Richon C; Meslin F; Faure F; Kauffmann A; Lecluse Y; Jalil A; Larue L; Avril MF; Chouaib S; Mehrpour M
Oncogene; 2006 Dec; 25(58):7618-34. PubMed ID: 16983347
[TBL] [Abstract][Full Text] [Related]
4. Imatinib mesylate inhibits tumorigenicity of malignant fibrous histiocytoma cells in vivo.
Irsan I; Akisue T; Hara H; Fujimoto T; Imabori M; Doita M; Kuroda R; Fujioka H; Kawamoto T; Yamamoto T; Kurosaka M
Anticancer Res; 2007; 27(1A):423-9. PubMed ID: 17352263
[TBL] [Abstract][Full Text] [Related]
5. Effects of imatinib vary with the types of KIT-mutation in gastrointestinal stromal tumor cell lines.
Noma K; Naomoto Y; Gunduz M; Matsuoka J; Yamatsuji T; Shirakawa Y; Nobuhisa T; Okawa T; Takaoka M; Tomono Y; Hiroyuki O; Gunduz E; Tanaka N
Oncol Rep; 2005 Sep; 14(3):645-50. PubMed ID: 16077968
[TBL] [Abstract][Full Text] [Related]
6. Effect of imatinib mesylate on neuroblastoma tumorigenesis and vascular endothelial growth factor expression.
Beppu K; Jaboine J; Merchant MS; Mackall CL; Thiele CJ
J Natl Cancer Inst; 2004 Jan; 96(1):46-55. PubMed ID: 14709738
[TBL] [Abstract][Full Text] [Related]
7. Imatinib inhibits proliferation of Ewing tumor cells mediated by the stem cell factor/KIT receptor pathway, and sensitizes cells to vincristine and doxorubicin-induced apoptosis.
González I; Andreu EJ; Panizo A; Inogés S; Fontalba A; Fernández-Luna JL; Gaboli M; Sierrasesúmaga L; Martín-Algarra S; Pardo J; Prósper F; de Alava E
Clin Cancer Res; 2004 Jan; 10(2):751-61. PubMed ID: 14760098
[TBL] [Abstract][Full Text] [Related]
8. Tyrosine kinase inhibitor imatinib modulates the viability and apoptosis of castrate-resistant prostate cancer cells dependently on the glycolytic environment.
Cardoso HJ; Vaz CV; Carvalho TMA; Figueira MI; Socorro S
Life Sci; 2019 Feb; 218():274-283. PubMed ID: 30605651
[TBL] [Abstract][Full Text] [Related]
9. Suppression of human prostate cancer cell growth by ciprofloxacin is associated with cell cycle arrest and apoptosis.
Aranha O; Grignon R; Fernandes N; McDonnell TJ; Wood DP; Sarkar FH
Int J Oncol; 2003 Apr; 22(4):787-94. PubMed ID: 12632069
[TBL] [Abstract][Full Text] [Related]
10. Imatinib mesylate (STI571) interference with growth of neuroectodermal tumour cell lines does not critically involve c-Kit inhibition.
Te Kronnie G; Timeus F; Rinaldi A; Crescenzio N; Spinelli M; Rosolen A; Ricotti E; Basso G
Int J Mol Med; 2004 Sep; 14(3):373-82. PubMed ID: 15289888
[TBL] [Abstract][Full Text] [Related]
11. Apoptotic effect of imatinib on human colon adenocarcinoma cells: influence on actin cytoskeleton organization and cell migration.
Popow-Woźniak A; Woźniakowska A; Kaczmarek L; Malicka-Błaszkiewicz M; Nowak D
Eur J Pharmacol; 2011 Sep; 667(1-3):66-73. PubMed ID: 21658383
[TBL] [Abstract][Full Text] [Related]
12. Imatinib mesylate inhibits Leydig cell tumor growth: evidence for in vitro and in vivo activity.
Basciani S; Brama M; Mariani S; De Luca G; Arizzi M; Vesci L; Pisano C; Dolci S; Spera G; Gnessi L
Cancer Res; 2005 Mar; 65(5):1897-903. PubMed ID: 15753388
[TBL] [Abstract][Full Text] [Related]
13. Green tea (-)-epigalocatechin-3-gallate inhibits KIT activity and causes caspase-dependent cell death in gastrointestinal stromal tumor including imatinib-resistant cells.
Chi HT; Vu HA; Iwasaki R; Thao le B; Hara Y; Taguchi T; Watanabe T; Sato Y
Cancer Biol Ther; 2009 Oct; 8(20):1934-9. PubMed ID: 19770581
[TBL] [Abstract][Full Text] [Related]
14. Imatinib mesylate (STI571; Glivec)--a new approach in the treatment of biliary tract cancer?
Wiedmann M; Kreth F; Feisthammel J; Deininger M; Mössner J; Caca K
Anticancer Drugs; 2003 Oct; 14(9):751-60. PubMed ID: 14551510
[TBL] [Abstract][Full Text] [Related]
15. Regulation of cell proliferation through a KIT-mediated mechanism in benign prostatic hyperplasia.
Imura M; Kojima Y; Kubota Y; Hamakawa T; Yasui T; Sasaki S; Hayashi Y; Kohri K
Prostate; 2012 Oct; 72(14):1506-13. PubMed ID: 22314612
[TBL] [Abstract][Full Text] [Related]
16. Synergistic interactions between DMAG and mitogen-activated protein kinase kinase 1/2 inhibitors in Bcr/abl+ leukemia cells sensitive and resistant to imatinib mesylate.
Nguyen TK; Rahmani M; Gao N; Kramer L; Corbin AS; Druker BJ; Dent P; Grant S
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2239-47. PubMed ID: 16609040
[TBL] [Abstract][Full Text] [Related]
17. Pseudolaric acid B induces apoptosis via proteasome-mediated Bcl-2 degradation in hormone-refractory prostate cancer DU145 cells.
Zhao D; Lin F; Wu X; Zhao Q; Zhao B; Lin P; Zhang Y; Yu X
Toxicol In Vitro; 2012 Jun; 26(4):595-602. PubMed ID: 22388098
[TBL] [Abstract][Full Text] [Related]
18. Imatinib inhibits c-Kit-induced hypoxia-inducible factor-1alpha activity and vascular endothelial growth factor expression in small cell lung cancer cells.
Litz J; Krystal GW
Mol Cancer Ther; 2006 Jun; 5(6):1415-22. PubMed ID: 16818499
[TBL] [Abstract][Full Text] [Related]
19. AKT mediates the pro-survival effects of KIT in ovarian cancer cells and is a determinant of sensitivity to imatinib mesylate.
Shaw TJ; Vanderhyden BC
Gynecol Oncol; 2007 Apr; 105(1):122-31. PubMed ID: 17169414
[TBL] [Abstract][Full Text] [Related]
20. Imatinib targeting of KIT-mutant oncoprotein in melanoma.
Jiang X; Zhou J; Yuen NK; Corless CL; Heinrich MC; Fletcher JA; Demetri GD; Widlund HR; Fisher DE; Hodi FS
Clin Cancer Res; 2008 Dec; 14(23):7726-32. PubMed ID: 19047099
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
